Qualigen Therapeutics, Inc. — Director's Dealing 2021

Apr 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Qualigen Therapeutics, Inc. (QLGN)
CIK: 0001460702
Period of Report: 2021-04-26

Reporting Person: BROIDRICK AMY S. (Director, EVP, Chief Strategy Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-26	Common Stock	P	4500	$2.03	Acquired	4500	Direct